Frequencies of KIR and KIR ligands in controls and cancer patients
| Control | Melanoma | Bladder | Ovarian | |
|---|---|---|---|---|
| KIR genes | (n = 621) | (n = 80) | (n = 80) | (n = 89) |
| KIR2DL1 | 606 (97.6%) | 79 (98.8%) | 75 (93.8%) | 86 (96.6%) |
| KIR2DL2 | 369 (59.4%) | 46 (57.5%) | 51 (63.8%) | 50 (56.2%) |
| KIR2DL3 | 558 (89.9%) | 75 (93.8%) | 66 (82.5%) | 80 (89.9%) |
| KIR2DL5 | 322 (51.9%) | 46 (57.5%) | 53 (66.3%)a | 47 (55.7%) |
| KIR3DL1 | 589 (94.8%) | 77 (96.3%) | 76 (95.0%) | 83 (93.3%) |
| KIR2DS1 | 248 (39.9%) | 35 (43.8%) | 39 (48.8%) | 36 (40.4%) |
| KIR2DS2 | 373 (60.1%) | 46 (57.5%) | 50 (62.5%) | 53 (59.6%) |
| KIR2DS3 | 198 (31.9%) | 27 (33.8%) | 33 (41.3%) | 31 (35.2%) |
| KIR2DS4 | 589 (94.8%) | 78 (97.5%) | 76 (95.0%) | 83 (93.3%) |
| KIR2DS5 | 181 (29.1%) | 33 (41.3%)b | 30 (37.5%) | 21 (23.9%) |
| KIR3DS1 | 256 (41.2%) | 36 (45.0%) | 39 (48.8%) | 38 (43.2%) |
| KIR ligands | ||||
| C1 | 528 (85.0%) | 64 (80.0%) | 59 (73.8%)c | 78 (87.6%) |
| C2 | 407 (65.5%) | 52 (65.0%) | 55 (68.8%) | 50 (56.2%) |
| Bw4 | 487 (78.4%) | 62 (77.5%) | 66 (82.5%) | 68 (76.4%) |
| A3/A11 | 199 (32.0%) | 21 (26.2%) | 28 (35.0%) | 28 (31.8%) |
| Licensing iKIR/ligand interactions | ||||
| KIR2DL1/C2 | 398 (64.1%) | 51 (63.8%) | 50 (62.5%) | 50 (56.2%) |
| KIR2DL2/C1 | 308 (49.6%) | 33 (41.2%) | 37 (46.3%) | 45 (50.6%) |
| KIR2DL3/C1 | 475 (76.5%) | 61 (76.2%) | 48 (60.0%)d | 66 (77.5%) |
| KIR3DL1/Bw4 | 464 (74.7%) | 60 (75.0%) | 62 (77.5%) | 63 (70.8%) |